![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/03/12/2844274/0/en/Azafaros-announces-completion-of-12-week-Phase-2-RAINBOW-study-evaluating-lead-asset-nizubaglustat-in-rare-disease-patients.html
https://www.globenewswire.com//news-release/2024/01/23/2813683/0/en/Azafaros-to-present-data-from-PRONTO-study-in-patients-with-GM1-and-GM2-gangliosidoses-at-the-20th-annual-WORLDSymposium.html
https://www.globenewswire.com//news-release/2023/12/11/2793532/0/en/Azafaros-Phase-2-RAINBOW-study-evaluating-nizubaglustat-in-GM2-and-NPC-patients-is-now-fully-enrolled.html
https://www.businesswire.com/news/home/20230220005101/en/Azafaros-Receives-Additional-Regulatory-Designations-for-AZ-3102-from-FDA-EMA-and-MHRA